These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 25414025)

  • 1. Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis.
    Drukker CA; Elias SG; Nijenhuis MV; Wesseling J; Bartelink H; Elkhuizen P; Fowble B; Whitworth PW; Patel RR; de Snoo FA; van 't Veer LJ; Beitsch PD; Rutgers EJ
    Breast Cancer Res Treat; 2014 Dec; 148(3):599-613. PubMed ID: 25414025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up.
    Turashvili G; Brogi E; Morrow M; Dickler M; Norton L; Hudis C; Wen HY
    BMC Cancer; 2018 Jan; 18(1):42. PubMed ID: 29304773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low risk of locoregional recurrence of primary breast carcinoma after treatment with a modification of the Halsted radical mastectomy and selective use of radiotherapy.
    Bijker N; Rutgers EJ; Peterse JL; van Dongen JA; Hart AA; Borger JH; Kroon BB
    Cancer; 1999 Apr; 85(8):1773-81. PubMed ID: 10223572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy.
    Truong PT; Olivotto IA; Kader HA; Panades M; Speers CH; Berthelet E
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1337-47. PubMed ID: 15817335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer.
    Gabos Z; Thoms J; Ghosh S; Hanson J; Deschênes J; Sabri S; Abdulkarim B
    Breast Cancer Res Treat; 2010 Nov; 124(1):187-94. PubMed ID: 20814819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Locoregional recurrence in breast carcinoma patients.
    Yildirim E
    Eur J Surg Oncol; 2009 Mar; 35(3):258-63. PubMed ID: 18644692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes.
    Truong PT; Berthelet E; Lee J; Kader HA; Olivotto IA
    Cancer; 2005 May; 103(10):2006-14. PubMed ID: 15812825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A nomogram for predicting locoregional recurrence in primary breast cancer patients who received breast-conserving surgery after neoadjuvant chemotherapy.
    Matsuda N; Hayashi N; Ohde S; Yagata H; Kajiura Y; Yoshida A; Suzuki K; Nakamura S; Tsunoda H; Yamauchi H
    J Surg Oncol; 2014 Jun; 109(8):764-9. PubMed ID: 24647874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors.
    Sjöström M; Staaf J; Edén P; Wärnberg F; Bergh J; Malmström P; Fernö M; Niméus E; Fredriksson I
    Breast Cancer Res; 2018 Jul; 20(1):64. PubMed ID: 29973242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers.
    Khan SS; Karn T; Symmans WF; Rody A; Müller V; Holtrich U; Becker S; Pusztai L; Hatzis C
    Breast Cancer Res Treat; 2015 Feb; 149(3):789-97. PubMed ID: 25651779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis in early stage triple-negative breast cancer treated with mastectomy without adjuvant radiotherapy: patterns of failure and prognostic factors.
    Chen X; Yu X; Chen J; Zhang Z; Tuan J; Shao Z; Guo X; Feng Y
    Cancer; 2013 Jul; 119(13):2366-74. PubMed ID: 23576181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphovascular invasion is associated with reduced locoregional control and survival in women with node-negative breast cancer treated with mastectomy and systemic therapy.
    Truong PT; Yong CM; Abnousi F; Lee J; Kader HA; Hayashi A; Olivotto IA
    J Am Coll Surg; 2005 Jun; 200(6):912-21. PubMed ID: 15922205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ten-year locoregional recurrence risks in women with nodal micrometastatic breast cancer staged with axillary dissection.
    Lupe K; Truong PT; Alexander C; Speers C; Tyldesley S
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e681-8. PubMed ID: 21300456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and pathologic risk factors of tumor recurrence in patients with node-negative early breast cancer after mastectomy.
    Lin PH; Yeh MH; Liu LC; Chen CJ; Tsui YC; Su CH; Wang HC; Liang JA; Chang HW; Wu HS; Yeh SP; Li LY; Chiu CF
    J Surg Oncol; 2013 Nov; 108(6):352-7. PubMed ID: 23996583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Locoregional failure 15 years after mastectomy in women with one to three positive axillary nodes with or without irradiation the significance of tumor size.
    Fodor J; Polgár C; Major T; Németh G
    Strahlenther Onkol; 2003 Mar; 179(3):197-202. PubMed ID: 12627264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients with t1 to t2 breast cancer with one to three positive nodes have higher local and regional recurrence risks compared with node-negative patients after breast-conserving surgery and whole-breast radiotherapy.
    Truong PT; Jones SO; Kader HA; Wai ES; Speers CH; Alexander AS; Olivotto IA
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):357-64. PubMed ID: 18676091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival benefit of post-mastectomy radiotherapy in breast carcinoma patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis.
    Duraker N; Demir D; Bati B; Yilmaz BD; Bati Y; Çaynak ZC; Sobutay E
    Jpn J Clin Oncol; 2012 Jul; 42(7):601-8. PubMed ID: 22511807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Locoregional recurrence after breast-conserving therapy remains an independent prognostic factor even after an event free interval of 10 years in early stage breast cancer.
    Tanis E; van de Velde CJ; Bartelink H; van de Vijver MJ; Putter H; van der Hage JA
    Eur J Cancer; 2012 Aug; 48(12):1751-6. PubMed ID: 22446021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic supraclavicular radiotherapy after surgery in high-risk n1 breast cancer.
    Yu JI; Park W; Shin KH; Lee NK; Choi DH; Huh SJ
    Oncology; 2013; 85(1):14-20. PubMed ID: 23797181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.